Research Reports
Medgenome Unlisted Shares
Medgenome Share Price
DMAT
PUBLIC LIMITED
Price Chart
1W
1M
1Y
MAX
High
₹2,328
Low
₹2,328
Return
-
Medgenome Essentials
As of April 30, 2026, Medgenome Labs, Unlisted Shares are trading at ₹2,328.00 per share and face value is ₹10.00/share, with a 52-week high of ₹2,328.00 and 52-week low of ₹2,328.00. The minimun lot size is None shares, and the shares are traded on .
ISIN
INE00K701014
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Shares
24,88,893
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Market Cap
579.41 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Hospitals & Diagnostics Centres
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Soonicorn
Category is defined as a class or division of things regarded as having particular shared characteristics.
About Medgenome
Company Overview:
- MedGenomeis a global leader in Genetic Testing services, Genomics Research, and drug discovery solutions. It operates a multi-pronged business model that capitalizes on the growing demand for personalized medicine and genetic insights.
- MedGenome has been committed to delivering world-class genomic solutions with greater precision and accuracy to empower every human being for better management of their health since 2013. MedGenome utilizes advanced technologies like Next-Generation Sequencing (NGS) for in-depth genetic analysis, aiding in complex diagnosis and personalized treatment plans.
- MedGenome is the only CAP-accredited Genetic testing lab in India that offers 1300+ genetic tests backed by the best and the latest testing technologies available across the world. MedGenome is dedicated to bringing the best precision testing solutions for quicker and smarter diagnosis of complex diseases. It operates the largest College of American Pathologists (CAP) accredited Next-Generation Sequencing (NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina's NovaSeq, HiSeq X, MiSeq, etc.
- MedGenome actively engages in research and development services, partnering with pharmaceutical companies and research institutions. This segment offers various services like collaborating on projects related to drug discovery, pharmacogenomics, and biomarker development; storing and managing biological samples for future research endeavors; and providing expertise and infrastructure to conduct genomics and personalized medicine trials.
- MedGenome recognized the value of strategic partnerships and collaboration with various entities including hospitals and clinics which expands their market reach and allows them to offer comprehensive care solutions to patients; pharmaceutical and research institutions which facilitate joint research projects, drug development initiatives, and clinical trials, accelerating advanced in the filed; technology companies which allow MedGenome to develop innovative solutions for data analysis, genetic testing, and personalized medicine applications.
- MedGenome Labs Limited was incorporated on 8 April 2013, with its registered office at No. 258/A,3rd Floor Narayana Nethralaya, Narayana Health City, Hosur Road, Bommasandra Bangalore Bangalore KA 560099 IN.
Want to See a Detailed Investment Analysis?
Explore in-depth financial analysis, performance metrics, and key disclosures.
Medgenome Media
News
Articles
Videos
‘Geographical expansions, augmented investments for new solutions to remain key focal areas for MedGenome’
07 Oct 2023
• Financial Express
MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test
09 Jul 2023
• Financial Express
MedGenome, backed by Sequoia Capital, acquires Delhi-NCR based Prognosis Laboratories
25 May 2023
• The Economic Times
Medgenome
₹ 2,328
